2026-07907Presidential DocumentWallet

White House Orders Fast-Track for Psychedelics to Treat Mental Illness

Published Date: 4/22/2026

Presidential Document

Summary

Millions of Americans, including many veterans, struggle with serious mental illnesses that current treatments don’t always fix. This new order speeds up research and approval of promising new therapies, like psychedelic drugs, to help those who haven’t found relief yet. Expect faster progress and more funding starting now to tackle this urgent health crisis.

Analyzed Economic Effects

5 provisions identified: 5 benefits, 0 costs, 0 mixed.

Pathway for Patient Access via Right to Try

The FDA and Drug Enforcement Administration must establish a pathway for eligible patients to access psychedelic drugs (including ibogaine compounds) under the Right to Try Act (21 U.S.C. 360bbb-0a). The order explicitly authorizes necessary Schedule I handling authorizations for treating physicians and researchers, consistent with 21 U.S.C. 823.

At Least $50 Million for State Psychedelic Programs

The Secretary of Health and Human Services, through the Advanced Research Projects Agency for Health, must allocate at least $50,000,000 from existing funds to support and partner with State governments that have or are developing programs to advance psychedelic drugs for serious mental illnesses. Funds may be used for Federal funding, technical assistance, and data sharing as appropriate and consistent with law.

HHS, FDA, and VA Data-Sharing and Trials Push

HHS and FDA must collaborate with the Department of Veterans Affairs and, where appropriate and lawful, with the private sector to increase clinical trial participation, data sharing, and real-world evidence generation for psychedelic drugs, prioritizing those with Breakthrough Therapy designation. The agencies are directed to sign data-sharing memoranda to make relevant clinical study data available to FDA to help timely evaluation under section 505 of the Federal Food, Drug, and Cosmetic Act.

Directive to Speed Drug Rescheduling Reviews

The Attorney General, in consultation with HHS, must initiate and complete review of any product containing a Schedule I substance that has successfully completed Phase 3 clinical trials for a serious mental health disorder so that rescheduling under 21 U.S.C. 811 may proceed as quickly as practicable for products ultimately approved under section 505 of the Federal Food, Drug, and Cosmetic Act.

Priority Vouchers for Psychedelic Breakthroughs

The Commissioner of Food and Drugs is ordered to provide Commissioner's National Priority Vouchers to appropriate psychedelic drugs that have received Breakthrough Therapy designation and meet the National Priority Voucher Program criteria. This is intended to prioritize FDA review of those psychedelic products.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Effective Date
Published Date
4/18/2026
4/22/2026

Department and Agencies

Department
Independent Agency
Agency
Executive Office of the President
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register